Marketing-authorisation holder · Netherlands
Recordati Netherlands B.V.
10 medicines in 3 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Netherlands
10 medicines in 3 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
10 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Fotivda | Tivozanib | EU (EMA) | Authorised | 2017 |
| FOTIVDACapsula rigida | Tivozanib | Italy | Authorised | |
| FOTIVDA 1340 MICROGRAMOS CAPSULAS DURAS1,5 mg · Cápsula dura | Tivozanib | Spain | Marketed | 2018 |
| FOTIVDA 890 MICROGRAMOS CAPSULAS DURAS1 mg · Cápsula dura | Tivozanib | Spain | Marketed | 2018 |
| QARZIBAConcentrato per soluzione per infusione | Dinutuximab beta | Italy | Authorised | |
| QARZIBA 4,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION4,5 mg · Concentrado para solución para perfusión | Dinutuximab beta | Spain | Marketed | 2018 |
| Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) | Dinutuximab beta | EU (EMA) | Authorised | 2017 |
| SYLVANTPolvere per concentrato per soluzione per infusione | Siltuximab | Italy | Authorised | |
| Sylvant | Siltuximab | EU (EMA) | Authorised | 2014 |
| SYLVANT 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION100 mg · Polvo para concentrado para solución para perfusión | Siltuximab | Spain | Marketed | 2014 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 3 | 3 | 0 | CompaniesAll medicines |
| Italy | 3 | 3 | 0 | CompaniesAll medicines |
Also in the registers of France
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.